Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Gulbas, Zafer  [Clear All Filters]
2024
Paviglianiti A, Ngoya M, Peña M, Boumendil A, Gulbas Z, Ciceri F, Bonifazi F, Russo D, Fegueux N, Stölzel F, et al. Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor. Bone Marrow Transplant. 2024.
Ferhatoglu F, Paksoy N, Khanmammadov N, Yildiz A, Ahmed MAydan, Gulbas Z, Başaran M. Therapeutic efficacy of high-dose chemotherapy with autologous stem-cell transplantation in 44 relapsed or refractory germ-cell tumor patients: A retrospective cohort study. Medicine (Baltimore). 2024;103(8):e37213.
2023
Deveci B, Ateşoğlu EBirtaş, Bayrak E, Kublashvili G, Toptaş T, Saba R, Gulbas Z. Comparative Efficacy and Safety of Beam and Team Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients. Transplant Proc. 2023.
Atesoglu EBirtas, Gulbas Z, Uzay A, Ozcan M, Özkalemkaş F, Dal MSinan, Kalyon H, Akay OMeltem, Deveci B, Bekoz H, et al. Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data. Hematol Oncol. 2023.
Meric N, Albayrak E, Gulbas Z, Kocabas F. MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis. Leuk Lymphoma. 2023:1-12.
Zinzani PLuigi Luig, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, Fogliatto LMaria, Garcia-Sancho AMartin, Christian B, Gulbas Z, et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170. Blood. 2023.
2022
Santoro N, Mooyaart JE, Devillier R, Koc Y, Vydra J, Castagna L, Gulbas Z, Martin JDiez, Araujo MColorado, Kulagin A, et al. Correction: Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party. Bone Marrow Transplant. 2022.
Mussetti A, Kanate AS, Wang T, He M, Hamadani M, Sr HFinel, Boumendil A, Glass B, Castagna L, Dominietto A, et al. Haploidentical versus matched unrelated donor transplants using post-transplant cyclophosphamide for lymphomas. Transplant Cell Ther. 2022.
Paksoy N, Ferhatoglu F, Dogan İ, Khanmammadov N, Celik AIribas, Gulbas Z, Başaran M. High-dose chemotherapy followed by autologous stem cell transplantation for adult patients With first relapse of Ewing's sarcoma: A single institution experience. Medicine (Baltimore). 2022;101(49):e32213.
2020
Maffini E, Labopin M, Blaise D, Ciceri F, Gulbas Z, Deconinck E, Leblond V, Chevallier P, Socié G, Araujo MColorado, et al. CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the European. Am J Hematol. 2020.
Bazarbachi A, Labopin M, Angelucci E, Gulbas Z, Ozdoğu H, Arat M, de Rosa L, Pastano R, Pioltelli P, Montserrat R, et al. Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party. Biol Blood Marrow Transplant. 2020.
Armand P, Murawski N, Molin D, Zain J, Eichhorst B, Gulbas Z, Hawkes EA, Pagel JM, Phillips T, Ribrag V, et al. Pembrolizumab in relapsed or refractory Richter syndrome. Br J Haematol. 2020.
2019
Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, Diez-Martin JL, Tischer J, Gulbas Z, Wallet HL, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol. 2019.
2018
Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, Peggs KS, Afanasyev B, Díez-Martín JL, Corradini P, et al. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer. 2018.
Aksoz M, Albayrak E, Aslan GServet, Turan RDilek, Alyazici LYazgi, Siyah P, Tusuz ECan, Canikyan S, Yucel D, Meric N, et al. c-Myc inhibitor 10074-G5 induces murine and human hematopoietic stem and progenitor cell expansion and HDR modulator Rad51 expression. Curr Cancer Drug Targets. 2018.
Shimoni A, Labopin M, Lorentino F, van Lint MTeresa, Koc Y, Gulbas Z, Tischer J, Bruno B, Blaise D, Pioltelli P, et al. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. Leukemia. 2018.
2013
Ozkan HAtilla, Bal C, Gulbas Z. Assessment and comparison of acute cardiac toxicity during high-dose cyclophosphamide and high-dose etoposide stem cell mobilization regimens with N-terminal pro-B-type natriuretic peptide. Transfus Apher Sci. 2013.
Sahin DGoren, Akay OMeltem, Teke HUsküdar, Andıc N, Gunduz E, Gulbas Z. Blastic plasmacytoid dendritic cell leukemia successfully treated by autologous hematopoietic stem cell transplantation to a remission of 48-month duration. Case Rep Hematol. 2013;2013:471628.